.Merck & Co.'s TIGIT plan has actually endured another misfortune. Months after shuttering a phas...
.After a year described through pipeline hairstyles, the shift of its chief executive officer and cu...
.Cullinan Therapy was thrilled enough with Harbour BioMed's bispecific immune system reactor that it...
.Within this week's incident of "The Leading Pipe," our team're diving in to Brutal Biotech's annual...
.The confetti is still flying coming from Eli Lilly's party commemorating the commendation of Alzhei...
.Welcome to this week's Chutes & Ladders, our roundup of significant management hirings, shooting...
.Adhering to an unsatisfactory presenting for Lykos Rehabs' MDMA applicant for post-traumatic stress...
.AN2 Rehabs is rethinking its own company in response to dull midphase records, promising to lay off...
.Merck & Co. is paying for $700 million beforehand to challenge Amgen in a blood stream cancer ce...
.Along With Gilead Sciences on the verge of an FDA selection for its own liver illness medication se...